Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation-Reference-Cited by-同舟云学术

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation

Published:2016-10-24 Issue:6 Volume:78 Page:1225-1235
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kiesel Brian F.,Parise Robert A.,Guo Jianxia,Huryn Donna M.,Johnston Paul A.,Colombo Raffaele,Sen Malabika,Grandis Jennifer R.,Beumer Jan H.,Eiseman Julie L.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-3181-9.pdf

Reference36 articles.

1. Geiger JL, Grandis JR, Bauman JE (2016) The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations. Oral Oncol 56:84–92. doi: 10.1016/j.oraloncology.2015.11.022

2. Argiris A (2015) EGFR inhibition for recurrent or metastatic HNSCC. Lancet Oncol 16(5):488–489. doi: 10.1016/s1470-2045(15)70178-6

3. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet (London, England) 371(9625):1695–1709. doi: 10.1016/s0140-6736(08)60728-x

4. Frank DA (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251(2):199–210. doi: 10.1016/j.canlet.2006.10.017

5. Wang X, Crowe PJ, Goldstein D, Yang JL (2012) STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol 41(4):1181–1191. doi: 10.3892/ijo.2012.1568

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiplatelet and Antithrombotic Properties of Compound L-36, a 6H-1,3,4-Thiadiazine Derivative;Bulletin of Experimental Biology and Medicine;2024-05

2. Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice;Cancer Chemotherapy and Pharmacology;2022-05-04

3. In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine;Cancer Chemotherapy and Pharmacology;2020-09-28

4. Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker;Cancer Chemotherapy and Pharmacology;2020-09-18

5. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a;Biomedicine & Pharmacotherapy;2020-09